Every Form 4 that MiNK Therapeutics, Inc. (INKT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INKT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INKT filings page.
MiNK Therapeutics, Inc. (symbol: INKT) is the issuer of record for a Form 4 filing submitted to the SEC.
MiNK Therapeutics, Inc. (symbol: INKT) is the issuer of record for a Form 4 filing submitted to the SEC.
MiNK Therapeutics, Inc. (symbol: INKT) is the issuer of record for a Form 4 filing submitted to the SEC.
MiNK Therapeutics, Inc. (symbol: INKT) is the issuer of record for a Form 4 filing submitted to the SEC.
MiNK Therapeutics, Inc. (symbol: INKT) is the issuer of record for a Form 4 filing submitted to the SEC.
MiNK Therapeutics director Barbara Ryan reported selling a total of 1,500 shares of Common Stock in open-market transactions. The sales on June 4, 2026 were executed at prices of $12.7995 for 1,000 shares and $12.6835 for 500 shares. Following these transactions, she directly holds 21,969 shares of MiNK Therapeutics common stock. According to the filing, the shares sold had been received as compensation for services as a member of the company’s Board of Directors.
Holcomb John Bradley reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics, Inc. director John Bradley Holcomb reported two stock-based compensation grants. On June 1, 2026, he received 1,091 shares of Common Stock as restricted stock units (RSUs) valued at $12.38 per share in lieu of cash board and committee retainers.
On March 2, 2026, he received an additional 1,239 RSU-based shares at $10.90 per share for Q1 2026 service. The filing notes these Q1 RSUs were not filed earlier due to an administrative error. After these awards, he directly holds 3,458 shares of MiNK Therapeutics common stock. The RSUs vest one month after each grant date, reflecting routine non-cash director compensation rather than open-market purchases.
MiNK Therapeutics director Barbara Ryan reported stock-based board compensation rather than open-market trades. On June 1, 2026, she received 1,434 shares of common stock valued at $12.38 per share as a grant in lieu of cash retainers, bringing her direct holdings to 23,469 shares.
The filing also reports a prior grant on March 2, 2026 of 1,629 shares at $10.90 per share, likewise received instead of cash board and committee fees. Footnotes explain these awards are restricted stock units that convert into one share each and vest one month after grant, and that the Q1 2026 RSUs were filed late due to an administrative error.
Corvese Brian reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics director Brian Corvese received stock-based board compensation rather than cash. He was granted 1,444 restricted stock units (RSUs) at $12.38 and 1,640 RSUs at $10.90 as compensation for board and committee retainers. The RSUs vest one month from each grant, and his direct common stock holdings total 53,137 shares after these awards. RSUs for Q1 2026 board and committee compensation were reported late due to an administrative error.
Behner Peter reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics, Inc. director Peter Behner reported stock-based board compensation. He received 1,313 restricted stock units on June 1, 2026 and 1,491 units on March 2, 2026, each convertible into common shares and granted in lieu of cash retainers. The RSUs vest one month after each grant, bringing his direct holdings to 22,919 common shares.
The company noted that the RSUs for Q1 2026 board and committee compensation were not filed on time due to an administrative error.
WIINBERG ULF reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics director Ulf Wiinberg reported stock-based board compensation rather than open-market trading. On June 1, 2026, he received 1,131 shares of Common Stock at $12.38 per share as a grant in lieu of cash retainers, bringing his direct holdings to 22,650 shares.
The filing also shows a prior grant of 1,285 shares on March 2, 2026 at $10.90 per share, with 21,519 shares held directly after that award. In addition, 27,830 shares are held indirectly in an irrevocable trust for the benefit of his family. Footnotes state these restricted stock units vest one month after grant and that the Q1 2026 grant was filed late due to an administrative error.
MiNK Therapeutics director John Bradley Holcomb received a grant of stock options covering 4,174 shares of common stock. The options have an exercise price of $14.92 per share and were awarded under the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan. They vest in three equal annual installments on September 23, 2026, 2027 and 2028, as long as Dr. Holcomb continues his service relationship with the company. Following this grant, he holds 4,174 options directly.
MiNK Therapeutics, Inc. director Barbara Ryan reported open-market sales of 1,500 shares of Common Stock. The transactions occurred on March 9–10, 2026 at prices between 10.1725 and 15.5652 per share. After these sales, she directly holds 20,406 shares of MiNK Therapeutics common stock.
According to the footnote, the shares sold were originally received as compensation for her services on the company’s Board of Directors, indicating the activity relates to monetizing equity-based director compensation rather than exercising options or derivatives.
MiNK Therapeutics, Inc. director Ryan Barbara reported selling a total of 500 shares of common stock in open-market transactions. The sales occurred on February 27, 2026 for 400 shares at $10.8583 per share and on March 2, 2026 for 100 shares at $10.8258 per share. After these trades, Barbara directly owned 21,906 shares of MiNK Therapeutics common stock.
MiNK Therapeutics, Inc. disclosed an amended insider trading report for its chief executive officer. The amendment updates a prior Form 4 to include 10,024 shares of common stock that were withheld on January 2, 2026 to cover withholding taxes related to stock issued to the executive. These shares were not originally shown in Table I of the earlier filing. After this tax withholding transaction at a reported price of $11.12 per share, the executive beneficially owns 57,942 shares of MiNK Therapeutics common stock in direct ownership. The amendment is described as correcting an error in the original Form 4 filed on January 6, 2026.
MiNK Therapeutics, Inc. reported that Chief Executive Officer Jennifer Buell received new equity awards. On January 2, 2026, she was granted 50,000 stock options with an exercise price of $11.12 per share, exercisable over a three-year vesting schedule, with one-third vesting on the one-year anniversary of the grant date and the remainder in eight equal quarterly installments.
On the same date, she also acquired 31,474 shares of common stock as her 2025 performance bonus, valued at $11.12 per share, which was the fair market value on the issuance date. These bonus shares are fully vested but subject to a lockup, with 100% of the award released on February 2, 2026. Following the stock grant, she directly owned 67,966 common shares.
MiNK Therapeutics director Ryan Barbara received a grant of 5,395 stock options on January 2, 2026. The options give the right to buy common stock at an exercise price of $11.12 per share and expire on February 2, 2036. According to the vesting terms, the option vests on February 2, 2026, provided Barbara continues to serve on the company’s board of directors through that date. After this grant, Barbara beneficially owns 5,395 derivative securities directly.
MiNK Therapeutics director Brian Corvese received a new stock option grant. On January 2, 2026, he was awarded options to buy 5,395 shares of MiNK Therapeutics common stock at an exercise price of $11.12 per share. These options vest on February 2, 2026, as long as he continues to serve on the company’s board through that date. The options expire on January 2, 2036, and were acquired at a price of $0.00, reflecting a compensatory equity award rather than a market purchase.
MiNK Therapeutics director reports new stock-based compensation. A company director received 1,263 restricted stock units (RSUs) of MiNK Therapeutics, Inc. common stock on 12/01/2025 at a value of $11.09 per share. These RSUs were granted in lieu of cash retainers for board and committee service and will vest one month after the grant date, at which point each RSU converts into one share of common stock. After this grant, the director beneficially owns 20,234 shares directly and 27,830 shares indirectly through an irrevocable trust established for the benefit of the director’s family.